Is Overexpression of the Plasma Membrane Transporter (SLC29A4) a New Option to Stratify Patients with High-Risk Neuroblastoma for Treatment with 131I-mIBG?

被引：0
|
作者：
Evers, Raymond [1 ]
机构：
[1] Janssen Pharmaceut, Preclin Sci & Translat Safety, Spring House, PA 19477 USA
来源：
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2023年 / 387卷 / 03期
关键词：
BIOLOGY;
D O I：
10.1124/jpet.123.001875
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：236 / 238
页数：3
相关论文
共 50 条
  • [1] The Role of 131I-MIBG in High-Risk Neuroblastoma Treatment
    Lessig, Megan Kinnear
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2009, 26 (04) : 208 - 216
  • [2] Upfront Treatment of High-Risk Neuroblastoma With a Combination of 131I-MIBG and Topotecan
    Kraal, Kathelijne C. J. M.
    Tytgat, Godelieve A. M.
    van Eck-Smit, Berthe L. F.
    Kam, Boen
    Caron, Huib N.
    van Noesel, Max
    PEDIATRIC BLOOD & CANCER, 2015, 62 (11) : 1886 - 1891
  • [3] Effectiveness of high-dose 131I-MIBG as consolidation therapy for the patients with high-risk neuroblastoma
    Inaki, A.
    Kuroda, R.
    Wakabayashi, H.
    Akatani, N.
    Yamase, T.
    Kunita, Y.
    Watanabe, S.
    Hiromasa, T.
    Mori, H.
    Saito, S.
    Ikawa, Y.
    Kayano, D.
    Kinuya, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S279 - S279
  • [4] Dosimetric evidences of 131I-MIBG treatment in High Risk Neuroblastoma in VERITAS protocol
    Saletti, P.
    Olianti, C.
    Tondo, A.
    Simontacchi, G.
    Belli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S225 - S225
  • [5] Radiation exposure in nurses during care of 131I-MIBG therapy for pediatric patients with high-risk neuroblastoma
    Yuka Taniguchi
    Hiroshi Wakabayashi
    Anri Inaki
    Daiki Kayano
    Masako Yamada
    Seigo Kinuya
    Annals of Nuclear Medicine, 2020, 34 : 441 - 447
  • [6] Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results
    Buckley, S.
    Flux, G.
    Gaze, M.
    Chittenden, S.
    Partridge, M.
    Lancaster, D.
    Pearson, A.
    Saran, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S339 - S339
  • [7] Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma:: Preliminary results
    Buckley, Susan E.
    Saran, Frank H.
    Gaze, Mark N.
    Chittenden, Sarah
    Partridge, Mike
    Lancaster, Donna
    Pearson, Andrew
    Flux, Glenn D.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (01) : 105 - 112
  • [8] CLINICAL IMPACT OF HIGH-DOSE 131I-MIBG THERAPY ON PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA
    Kuroda, Rie
    Nishimura, Ryosei
    Araki, Raita
    Takenaka, Mika
    Sakai, Yuta
    Noguchi, Kazuhiro
    Fujiki, Toshihiro
    Ikawa, Yasuhiro
    Wada, Taizo
    PEDIATRIC BLOOD & CANCER, 2024, 71 : S14 - S15
  • [9] A Diagnostic Use Of Post-therapy 131I-mibg Scintigraphy In Pediatric Patients With High-risk Neuroblastoma
    Wakabayashi, H.
    Kayano, D.
    Inaki, A.
    Araki, R.
    Maeba, H.
    Kuroda, R.
    Akatani, N.
    Yamase, T.
    Watanabe, S.
    Hiromasa, T.
    Mori, H.
    Kunita, Y.
    Nguyen, N.
    Kinuya, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S622 - S622
  • [10] Radiation exposure in nurses during care of 131I-MIBG therapy for pediatric patients with high-risk neuroblastoma
    Taniguchi, Yuka
    Wakabayashi, Hiroshi
    Inaki, Anri
    Kayano, Daiki
    Yamada, Masako
    Kinuya, Seigo
    ANNALS OF NUCLEAR MEDICINE, 2020, 34 (06) : 441 - 447
12345